Udenafil
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H318964

CAS#: 268203-93-6

Description: Udenafil is an inhibitor of phosphodiesterase 5 (PDE5). In vivo, udenafil increases lung cGMP levels, attenuates the development of compensatory right ventricular hypertrophy, and reduces pulmonary arterial wall thickening. It increases creatine clearance and decreases blood urea nitrogen (BUN) and serum malondialdehyde (MDA) levels in a rat model of renal ischemia-reperfusion injury. Udenafil also induces penile erections in conscious rabbits and in rabbits with acute spinal cord injury.

Chemical Structure

img
Udenafil
CAS# 268203-93-6
Instruction

Theoretical Analysis

Hodoodo Cat#: H318964
Name: Udenafil
CAS#: 268203-93-6
Chemical Formula: C25H36N6O4S
Exact Mass: 516.25
Molecular Weight: 516.661
Elemental Analysis: C, 58.12; H, 7.02; N, 16.27; O, 12.39; S, 6.21

Price and Availability

Size Price Availability Quantity
10mg USD 250 2 Weeks
25mg USD 450 2 Weeks
100mg USD 950 2 Weeks
Bulk inquiry

Synonym: DA-8159, DA 8159, DA8159, Udenafil, Zydena

IUPAC/Chemical Name: 3-(1-methyl-7-oxo-3-propyl-4,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide

InChi Key: IYFNEFQTYQPVOC-UHFFFAOYSA-N

InChi Code: InChI=1S/C25H36N6O4S/c1-5-8-20-22-23(31(4)29-20)25(32)28-24(27-22)19-16-18(10-11-21(19)35-15-6-2)36(33,34)26-13-12-17-9-7-14-30(17)3/h10-11,16-17,26H,5-9,12-15H2,1-4H3,(H,27,28,32)

SMILES Code: O=S(C1=CC=C(OCCC)C(C(NC2=C3N(C)N=C2CCC)=NC3=O)=C1)(NCCC4N(C)CCC4)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 516.66 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Kim TH, Ha YS, Choi SH, Yoo ES, Kim BW, Yun SJ, Kim WJ, Kwon YS, Kwon TG. Factors predicting outcomes of penile rehabilitation with udenafil 50 mg following radical prostatectomy. Int J Impot Res. 2015 Oct 29. doi: 10.1038/ijir.2015.28. [Epub ahead of print] PubMed PMID: 26510966.

2: Lee TY, Choi JS, Oh HC, Song TJ, Do JH, Cheon YK. Oral udenafil and aceclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a randomized multicenter study. Korean J Intern Med. 2015 Sep;30(5):602-9. doi: 10.3904/kjim.2015.30.5.602. Epub 2015 Aug 27. PubMed PMID: 26354054; PubMed Central PMCID: PMC4578023.

3: Seftel AD. Re: Efficacy of Once-Daily Administration of Udenafil for 24 Weeks on Erectile Dysfunction: Results from a Randomized Multicenter Placebo-Controlled Clinical Trial. J Urol. 2015 Aug;194(2):495. doi: 10.1016/j.juro.2015.05.063. Epub 2015 May 18. PubMed PMID: 26195408.

4: Kim KH, Kim HK, Hwang IC, Cho HJ, Je N, Kwon OM, Choi SJ, Lee SP, Kim YJ, Sohn DW. PDE 5 inhibition with udenafil improves left ventricular systolic/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction; A 12-week, randomized, double-blind, placebo-controlled trial. Am Heart J. 2015 Jun;169(6):813-822.e3. doi: 10.1016/j.ahj.2015.03.018. Epub 2015 Apr 1. PubMed PMID: 26027619.

5: Seftel AD. Re: Comparison of the efficacy and safety of once-daily dosing and on-demand use of udenafil for type 2 diabetic patients with erectile dysfunction. J Urol. 2015 Apr;193(4):1326. doi: 10.1016/j.juro.2015.01.055. Epub 2015 Jan 20. PubMed PMID: 25890547.

6: Kim HL, Kim YJ, Kim KH, Lee SP, Kim HK, Sohn DW, Oh BH, Park YB. Therapeutic effects of udenafil on pressure-overload cardiac hypertrophy. Hypertens Res. 2015 Sep;38(9):597-604. doi: 10.1038/hr.2015.46. Epub 2015 Apr 2. PubMed PMID: 25832922.

7: Kim YH, Choi HY, Lee SH, Jeon HS, Lim HS, Bahng MY, Bae KS. Pharmacokinetic interaction between udenafil and dapoxetine: a randomized, open-labeled crossover study in healthy male volunteers. Drug Des Devel Ther. 2015 Feb 23;9:1209-16. doi: 10.2147/DDDT.S78713. eCollection 2015. PubMed PMID: 25759565; PubMed Central PMCID: PMC4346016.

8: Moon KH, Ko YH, Kim SW, Moon du G, Kim JJ, Park NC, Lee SW, Paick JS, Ahn TY, Chung WS, Min KS, Park JK, Yang DY, Park K. Efficacy of once-daily administration of udenafil for 24 weeks on erectile dysfunction: results from a randomized multicenter placebo-controlled clinical trial. J Sex Med. 2015 May;12(5):1194-201. doi: 10.1111/jsm.12862. Epub 2015 Mar 4. PubMed PMID: 25736397.

9: Cao DH, Liu LR, Wei Q. Commentary on - "Comparison of the efficacy and safety of once-daily dosing and on-demand use of udenafil for type 2 diabetic patients with erectile dysfunction". Asian J Androl. 2015 Sep-Oct;17(5):854. doi: 10.4103/1008-682X.148069. PubMed PMID: 25652635; PubMed Central PMCID: PMC4577604.

10: Kreisel W, Deibert P, Kupcinskas L, Sumskiene J, Appenrodt B, Roth S, Neagu M, Rössle M, Zipprich A, Caca K, Ferlitsch A, Dilger K, Mohrbacher R, Greinwald R, Sauerbruch T. The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study. Dig Liver Dis. 2015 Feb;47(2):144-50. doi: 10.1016/j.dld.2014.10.018. Epub 2014 Nov 15. PubMed PMID: 25483910.

11: Park SY, Choi GS, Park JS, Kim HJ, Park JA, Choi JI. Efficacy and safety of udenafil for the treatment of erectile dysfunction after total mesorectal excision of rectal cancer: a randomized, double-blind, placebo-controlled trial. Surgery. 2015 Jan;157(1):64-71. doi: 10.1016/j.surg.2014.07.007. PubMed PMID: 25482466.

12: Park JK, Park EA, Lee W, Kim YK, Lee EY, Song YW, Lee EB. Baseline MRA predicts the treatment response to vasodilator udenafil in patients with secondary Raynaud's phenomenon. Clin Exp Rheumatol. 2014 Nov-Dec;32(6 Suppl 86):S-167-70. Epub 2014 Sep 5. PubMed PMID: 25189168.

13: Park SH, Park SW, Cha BY, Park IeB, Min KW, Sung YA, Kim TH, Lee JM, Park KS. Comparison of the efficacy and safety of once-daily dosing and on-demand use of udenafil for type 2 diabetic patients with erectile dysfunction. Asian J Androl. 2015 Jan-Feb;17(1):143-8. doi: 10.4103/1008-682X.135983. PubMed PMID: 25155105; PubMed Central PMCID: PMC4291858.

14: Fang CH, Song YS, So BI, Kim H, Shin JH, Kim KS. Concentration-dependent differential effects of udenafil on viability, proliferation, and apoptosis in vascular endothelial and smooth muscle cells. Indian J Pharmacol. 2014 May-Jun;46(3):292-7. doi: 10.4103/0253-7613.132161. PubMed PMID: 24987176; PubMed Central PMCID: PMC4071706.

15: Cho MC, Paick JS. Udenafil for the treatment of erectile dysfunction. Ther Clin Risk Manag. 2014 May 14;10:341-54. doi: 10.2147/TCRM.S39727. eCollection 2014. Review. PubMed PMID: 24868160; PubMed Central PMCID: PMC4027935.

16: Özgür BC, Telli O, Yuceturk CN, Sarici H, Ozer E, Surer H, Kılınc AS, Hucumenoglu S, Eroglu M. The effect of sildenafil and udenafil on testicular damage following ischemia-reperfusion injury in rats. J Urol. 2014 Oct;192(4):1272-7. doi: 10.1016/j.juro.2014.04.011. Epub 2014 Apr 15. PubMed PMID: 24742592.

17: Lee EY, Park JK, Lee W, Kim YK, Park CS, Giles JT, Park JW, Shin K, Lee JS, Song YW, Lee EB. Head-to-head comparison of udenafil vs amlodipine in the treatment of secondary Raynaud's phenomenon: a double-blind, randomized, cross-over study. Rheumatology (Oxford). 2014 Apr;53(4):658-64. doi: 10.1093/rheumatology/ket417. Epub 2013 Dec 17. PubMed PMID: 24352340.

18: Neĭmark BA, Neĭmark AI, Tishchenko GE. [Application of udenafil for the correction of endothelial disorders in patients with stress-induced erectile dysfunction]. Urologiia. 2013 Jul-Aug;(4):42-4, 46. Russian. PubMed PMID: 24159764.

19: Kim KH, Kim HK, Hwang IC, Lee SP, Cho HJ, Kang HJ, Kim YJ, Sohn DW. ULTIMATE-SHF trial (UdenafiL Therapy to Improve symptoMAtology, exercise Tolerance and hEmodynamics in patients with chronic systolic heart failure): study protocol for a randomized, placebo-controlled, double-blind trial. Trials. 2013 Jun 22;14:188. doi: 10.1186/1745-6215-14-188. PubMed PMID: 23799908; PubMed Central PMCID: PMC3694004.

20: Ortaç M, Çayan S, Çalişkan MK, Yaman MÖ, Okutucu TM, Semerci MB, Altay AB, Balbay MD, Özcan MF, Kadioğlu A. Efficacy and tolerability of udenafil in Turkish men with erectile dysfunction of psychogenic and organic aetiology: a randomized, double-blind, placebo-controlled study. Andrology. 2013 Jul;1(4):549-55. doi: 10.1111/j.2047-2927.2013.00085.x. PubMed PMID: 23785019.